Videos

A urology specialist reviews the case of a 78-year-old patient with metastatic prostate cancer, analyzes their risk level and prognosis, and discusses frontline treatment.

Paul M. Yonover, MD, FACS, reviews treatment options available for patients with high-risk prostate cancer following radical prostatectomy.

A comprehensive overview of treatment options available for patients with prostate cancer and factors that influence treatment decisions.

An expert on prostate cancer discusses the clinical application of imaging and biomarker testing for patients with prostate cancer.

Paul M. Yonover, MD, FACS, a urology specialist, reviews the case of a 66-year-old man with prostate cancer and offers his initial impressions.

“So many times, partners were left in the dark. They didn't have a clue what their partner who had prostate cancer was going through, and we felt that we could fill that void,” says Neil H. Baum, MD.

“What we're thinking here is that surgeon sex is a surrogate for a whole series of behaviors driven by sociologic conditioning of how people interact with each other and how physicians practice medicine,” says Christopher J.D. Wallis, MD, PhD.

“We found that over 40% of patients with muscle-invasive bladder cancer are not receiving cystectomy or trimodal therapy,” says James Ferguson III, MD, PhD.

“I think the other thing that was surprising was that this allowed us to really pinpoint where we were dragging our feet,” says Randall A. Lee, MD.

“We have over 400 abstracts submitted this year to the SMSNA, which is really outstanding. We're looking at a record in terms of attendance this year, and we're very excited to have this,” says Mohit Khera, MD, MBA, MPH.

Factors impacting the choice between gallium 68 and fluorine 18 PSMA PET tracers, including half-lives, institutional capabilities, access to resources, detection rates, reimbursement constraints, and potential differences in interpretation.

Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, discuss the consensus between clinical guidelines for PSMA PET CT usage in prostate cancer, emphasizing multidisciplinary collaboration and the importance of urologists' involvement.

“The driving force for this was understanding whether we have made improvements as surgeons over time in how we're able to remove the prostate, but then also what types of functional outcomes patients have with regards to urinary function and sexual function,” says Udit Singhal, MD.

“There's going to be new techniques that we're not even aware of yet to try and break up the stones in a better fashion, but in a less invasive way for patients,” says Ben H. Chew, MD, MSc, FRCSC.

"Patients who have a female surgeon are about 25% less likely to die than if they had a male surgeon," says Christopher J.D. Wallis, MD, PhD.

“As we increase spending, we know there are good data out there that we haven't seen reflective improvement in outcomes or decreasing complications when we treat our patients,” says Randall A. Lee, MD.

Expert urologist Naveen Kella, MD, shares his perspective on the advent of PSMA PET-CT imaging in patients with prostate cancer, addressing both benefits and limitations to this approach.

"We're currently doing a multicenter, prospective study using the new Boston Scientific scope to measure intrarenal pressure for every ureteroscopy that we perform to get more data and to be able to identify these patients earlier, before they get septic," says Naeem Bhojani, MD, FRCSC.

“Another effort could be querying recent applicants or current applicants and seeing what information about diversity, equity, and inclusion would be important to them,” says Keiko Cooley, MD.

"It was really wonderful to work with a lot of our coauthors for the chapters because they really are thought leaders in the field," says Edward M. Schaeffer, MD, PhD.

The radionuclide-drug conjugate 225Ac-J591 combines J591, a monoclonal antibody that recognizes PSMA, with actinium-225, a potent alpha emitter.

"Just really try to have awareness; figure out, what do you really need right now? Once you realize what you need, have compassion, stop the judgment," says Diana Londoño, MD.

"What we found was that if during ureteroscopy your intrarenal pressure remains below 30 mm of mercury, there shouldn't be any infectious complications," says Naeem Bhojani, MD, FRCSC.

In the first interview of the series, Nilay Gandhi, MD, provides an overview of advanced/metastatic prostate cancer and the role of androgen deprivation therapy in treating patients.

"I think that there could have been some expectation to see this lack of advertisement or engagement with DEI, particularly in urology given its current demographics," says Keiko Cooley, MD.

Key opinion leaders discuss how PSMA PET CT tracers, including gallium 68 and fluorine 18, are revolutionizing prostate cancer patient management and with accurate and early detection of disease spread.

A review of available PSMA PET tracers for prostate cancer detection, covering sensitivity, specificity, access to therapy, and reimbursement impacting patient care.

“Where I have found that it has been incredibly useful has been in those unfavorable intermediate-risk patients or those individuals who are kind of borderline at the risk spectrum,” says Rana R. McKay, MD.

“The purpose of the course is really to bring together like-minded surgeons and physicians who are interested in robotic reconstructive surgery to really come together to not only build a network, but also discuss complex situations, discuss tips and tricks, and also to review the most salient literature in this space,” says Ziho Lee, MD.

"Given that these lesions are common, even if surgeons aren't treating adrenal tumors, they're certainly going to find some on imaging," says Neal E. Rowe, MD, FRCSC.